Compare · NVO vs TYRA
NVO vs TYRA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Tyra Biosciences Inc. (TYRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TYRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $184.18B, about 135.0x TYRA ($1.36B).
- NVO has been more active in the news (9 items in the past 4 weeks vs 4 for TYRA).
- NVO has more recent analyst coverage (25 ratings vs 21 for TYRA).
- Company
- Novo Nordisk A/S
- Tyra Biosciences Inc.
- Price
- -
- -
- Market cap
- $184.18B
- $1.36B
- 1M return
- +7.16%
- -
- 1Y return
- -14.17%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 4
- Recent ratings
- 25
- 21
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Tyra Biosciences Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest TYRA
- SEC Form 10-Q filed by Tyra Biosciences Inc.
- Tyra Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
- Tyra Biosciences to Participate in Upcoming Investor Conferences
- SEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.
- President and CEO Harris Todd was granted 864 shares, increasing direct ownership by 0.06% to 1,438,495 units (SEC Form 4)
- Vice President, Finance (PAO) Rueb Yuliya was granted 2,925 shares, increasing direct ownership by 35% to 11,258 units (SEC Form 4)
- Chief Financial Officer Fuhrman Alan was granted 951 shares, increasing direct ownership by 3% to 37,115 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Tyra Biosciences Inc.
- SEC Form 4 filed by Director Ra Capital Management, L.P.